What were the results of the Parkinson's Progression Markers Initiative (PPMI)?

Updated: Aug 29, 2019
  • Author: Robert A Hauser, MD, MBA; Chief Editor: Selim R Benbadis, MD  more...
  • Print

In the "Parkinson's Progression Markers Initiative" cross-sectional study of 63 drug-naive patients with early-stage PD and 39 healthy controls, CSF levels of the Alzheimer's biomarkers β-amyloid 1-42 (Aβ1-42), total tau (T-tau), tau phosphorylated at threonine 181 (P-tau181), and α-synuclein were lower in the PD patients than in the controls. Aβ1-42 and P-tau181 were significant predictors of Parkinson's disease, and T-tau and α-synuclein were associated with the severity of motor dysfunction. In particular, lower Aβ1-42 and P-tau181 concentrations were associated with the postural instability–gait disturbance–dominant PD phenotype, but were not associated with the tremor-dominant or intermediate phenotypes. [41, 42]

See Lumbar Puncture for detailed information on indications for the procedure, contraindications, and a step-by-step discussion containing images and video on how to perform the procedure.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!